Malaysian Diabetes Devices Market, Forecast to 2023

Malaysian Diabetes Devices Market, Forecast to 2023

Service Models that Address Affordability are the Preferred Models in this Cost-sensitive Market

RELEASE DATE
07-Feb-2020
REGION
Asia Pacific
Research Code: PABF-01-00-00-00
SKU: HC03268-AP-MR_24135

$3,000.00

Special Price $2,250.00 save 25 %

In stock
SKU
HC03268-AP-MR_24135

$3,000.00

$2,250.00 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Diabetes is a growing concern globally, with more than 425 million people suffering the world over. Malaysia is no exception. It has a very high prevalence of about 16%; there were an estimated 3.57 million diabetics in the country in 2018. Unfortunately, only about 50% of this population is actually diagnosed, meaning half of those diabetics are diagnosed only at later stages, often after complications arise; complications that decrease quality of life but increase the cost of care.

As Malaysians are predominantly uninsured or do not have coverage for diabetes management devices, their glucose levels tend to be irregularly monitored. This results in even the diagnosed population developing health complications from the condition. The market potential for diabetes devices in Malaysia or other Asia-Pacific countries is huge but is hampered by access and affordability. For any company targeting these markets, it is crucial that it understands the current competitive landscape; reimbursement and regulatory policies; and the distribution structure, to determine its opportunity and the best go-to-market strategy.

There are four categories of medical devices that are crucial for diabetics: self-monitoring of blood glucose (SMBG) and the professional point-of-care testing (POCT); continuous glucose monitoring (CGM); insulin pens; and insulin pumps. Broadly, these devices can be classified under monitoring (SMBG, POCT, and CGM), and management (insulin pens and insulin pumps).

Most of the countries in the Asia-Pacific region import these devices. Multinational majors, and in the case of SMBG some low-cost manufacturers from China and Taiwan cater to the demand for diabetes devices. Some of the major names in the SMBG and POCT testing space are Roche, Abbott, LifeScan, and Ascensia Diabetes Care. In the case of CGM, Medtronic dominates Asia-Pacific, as global majors Dexcom and Abbott have not yet ventured into this region. The insulin pen segment is dominated by Novo Nordisk, Sanofi, and Eli Lilly, though a few other participants (for e.g., Biocon from India) may also be present, depending on the country in question. The insulin pump segment too is also dominated by Medtronic; however, the South Korean SOOIL Development is present in a few APAC countries. Medtronic supplies either a basic and/or an advanced version of its pumps, depending on the country in question. Other western players such as Insulet have not yet entered this market.

This study provides an in-depth view of each of the 4 segments: SMBG and POCT; CGM; insulin pens; and insulin pumps through the analyses of drivers, restraints, revenue forecasts, average selling prices of products and consumables, the market shares of top participants, their market strategies, and route to market. In addition, it provides a country-level overview of public health policies for diabetics, reimbursement and regulatory insights, and offers distribution insights by highlighting key distributors and growth opportunities in the country.

Author: Siddharth Shah

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Key Findings

Key Findings (continued)

Diabetes Prevalence and Diagnosis Trends

Diabetes Devices Market Participants

Diabetes Devices Market Participants (continued)

Malaysia Glucose Monitoring and Diabetes Management

Distribution Insights—Malaysia

Market Definitions

Scope and Segmentation

Market Revenue Forecast by Device Type

Revenue Forecast Discussion

Market Drivers

Market Restraints

Revenue Forecast by Device Type

Revenue Forecast Discussion

Revenue Forecast by Application

Revenue Forecast Discussion

Personal and Pharmacy SMBG Devices Market Share

Hospital SMBG and POCT Professional Testing Market Share

SMBG Devices Market Participant Strategy

POCT Devices Market Participant Strategy

SMBG Route-to-Market Analysis

Market Drivers

Market Restraints

Revenue Forecast by Device Type

Revenue Forecast Discussion

Market Share

Market Participant Strategy

Route-to-Market Analysis

Market Drivers

Market Restraints

Revenue Forecast

Revenue Forecast Discussion

Market Share

Market Participant Strategy

Route-to-Market Analysis

Market Drivers

Market Restraints

Revenue Forecast

Revenue Forecast Discussion

Market Share

Market Participant Strategy

Route-to-Market Analysis

Country Policies for Diabetes

Diabetes Device Regulatory Insights

Reimbursement and Insurance Insights

Route to Market

Key Distributors

Growth Opportunity 1—Unlocking Untapped Potential

Growth Opportunity 2—Glucose Testing in Pharmacies

Strategic Imperatives for Success and Growth

3 Big Predictions

Legal Disclaimer

List of Exhibits

List of Exhibits (continued)

List of Exhibits (continued)

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
Diabetes is a growing concern globally, with more than 425 million people suffering the world over. Malaysia is no exception. It has a very high prevalence of about 16%; there were an estimated 3.57 million diabetics in the country in 2018. Unfortunately, only about 50% of this population is actually diagnosed, meaning half of those diabetics are diagnosed only at later stages, often after complications arise; complications that decrease quality of life but increase the cost of care. As Malaysians are predominantly uninsured or do not have coverage for diabetes management devices, their glucose levels tend to be irregularly monitored. This results in even the diagnosed population developing health complications from the condition. The market potential for diabetes devices in Malaysia or other Asia-Pacific countries is huge but is hampered by access and affordability. For any company targeting these markets, it is crucial that it understands the current competitive landscape; reimbursement and regulatory policies; and the distribution structure, to determine its opportunity and the best go-to-market strategy. There are four categories of medical devices that are crucial for diabetics: self-monitoring of blood glucose (SMBG) and the professional point-of-care testing (POCT); continuous glucose monitoring (CGM); insulin pens; and insulin pumps. Broadly, these devices can be classified under monitoring (SMBG, POCT, and CGM), and management (insulin pens and insulin pumps). Most of the countries in the Asia-Pacific region import these devices. Multinational majors, and in the case of SMBG some low-cost manufacturers from China and Taiwan cater to the demand for diabetes devices. Some of the major names in the SMBG and POCT testing space are Roche, Abbott, LifeScan, and Ascensia Diabetes Care. In the case of CGM, Medtronic dominates Asia-Pacific, as global majors Dexcom and Abbott have not yet ventured into this region. The insulin pen segment is dominated by Novo Nordisk, Sanofi, and Eli Lilly, though a few other participants (for e.g., Biocon from India) may also be present, depending on the country in question. The insulin pump segment too is also dominated by Medtronic; however, the South Korean SOOIL Development is present in a few APAC countries. Medtronic supplies either a basic and/or an advanced version of its pumps, depending on the country in question. Other western players such as Insulet have not yet entered this market. This study provides an in-depth view of each of the 4 segments: SMBG and POCT; CGM; insulin pens; and insulin pumps through the analyses of drivers, restraints, revenue forecasts, average selling prices of products and consumables, the market shares of top participants, their market strategies, and route to market. In addition, it provides a country-level overview of public health policies for diabetics, reimbursement and regulatory insights, and offers distribution insights by highlighting key distributors and growth opportunities in the country. Author: Siddharth Shah
More Information
No Index No
Podcast No
Author Siddharth Shah
Industries Healthcare
WIP Number PABF-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9A49-B1,9A4B-B1